We employed a three-stage modelling approach , which included development of ( 1 ) a baseline 24-h ABPM model , ( 2 ) a pharmacokinetic model from serial and sparse pharmacokinetic data , and ( 3 ) an indirect-response , maximum-effect ( Emax ) model to evaluate the exposure-driven effect of axitinib on dBP .